Blockage of interleukin-1β with canakinumab in patients with Covid-19

Blockage of interleukin-1β with canakinumab in patients with Covid-19

Abstract There is the urgent need to study the effects of immunomodulating agents as therapy for Covid-19. An observational, cohort, prospective study with 30 days of observation was carried out to assess clinical outcomes in 88 patients hospitalized for Covid-19 pneumonia and treated with canakinum...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Lorenza Landi, Claudia Ravaglia, Emanuele Russo, Pierluigi Cataleta, Maurizio Fusari, Andrea Boschi, Diana Giannarelli, Francesca Facondini, Ilaria Valentini, Ilaria Panzini, Luigi Lazzari-Agli, Paolo Bassi, Elisa Marchionni, Rossella Romagnoli, Raffaella De Giovanni, Marina Assirelli, Federica Baldazzi, Fabio Pieraccini, Giovanna Rametta, Lucia Rossi, Luca Santini, Ivana Valenti, Federico Cappuzzo
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/c6f76dd0ab04416d8577e6754667f409
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/c6f76dd0ab04416d8577e6754667f409

Ejemplares similares